Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$14.76 USD

14.76
1,862,996

+0.28 (1.93%)

Updated Aug 26, 2026 03:55 PM ET

After-Market: $14.76 0.00 (0.00%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact

by Zacks Equity Research

Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.

    Zacks Equity Research

    Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

    by Zacks Equity Research

    Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

      Arpita Dutt headshot

      Generic Drugmakers Tumble as Perrigo Discloses DoJ Search

      by Arpita Dutt

      With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.

        Zacks Equity Research

        Perrigo Launches First to Market OTC Equivalent of Rogaine

        by Zacks Equity Research

        Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).

          Zacks Equity Research

          Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View

          by Zacks Equity Research

          The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.

            Zacks Equity Research

            Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?

            by Zacks Equity Research

            Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.

              Zacks Equity Research

              Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

              by Zacks Equity Research

              Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.

                Zacks Equity Research

                Is Perrigo Company (PRGO) a Great Stock for Value Investors?

                by Zacks Equity Research

                Let's delve into the value metrics of Perrigo Company (PRGO) and determine whether it is a good value investment right now.

                  Mark Vickery headshot

                  So Much for a Trump Win Tanking the Market

                  by Mark Vickery

                  Once the smoke cleared from the surprise election results, market participants now see a clear path to increased growth and prosperity.

                    Zacks Equity Research

                    Stock Market News for August 10, 2016

                    by Zacks Equity Research

                    Benchmarks closed narrowly in the green as drop in oil prices and disappointing productivity data offset some of the gains in healthcare and consumer staples stocks